Cu(bta)(1,10-phen)ClO4 copper complex modulates the carcinogenicity of carboplatin in somatic cells of Drosophila melanogaster
Chemotherapy stands out as the main systemic treatment strategy against cancer and still faces problems related to multidrug resistance and severe side effects. Copper-based drugs have been widely explored in medicinal chemistry, since copper is an essential metal for physiological activities with a...
Saved in:
Published in | Genetics and molecular biology Vol. 47; no. 3; p. 1 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English Portuguese |
Published |
Ribeirao Preto
Sociedade Brasileira de Genetica
2024
Sociedade Brasileira de Genética |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Chemotherapy stands out as the main systemic treatment strategy against cancer and still faces problems related to multidrug resistance and severe side effects. Copper-based drugs have been widely explored in medicinal chemistry, since copper is an essential metal for physiological activities with antineoplastic effects. In this context, the present study aimed to evaluate the recombinogenic/mutagenic and anticarcinogenic potential of the complex CBP-01 - [Cu(bta)(1,10-phen)ClO4] (Hbta = 4,4,4-trifluoro-1-phenyl-1,3-butanedione and 1,10-phen =1,10-phenanthroline) - through the Somatic and Recombination test (SMART) and the Epithelial Tumor Test (ETT) in Drosophila melanogaster, compared with carboplatin (CARB) and cisplatin (CIS) effects. According to our results, CARB and CIS induced a high frequency of mutant spots, which was not verified at higher concentrations of CBP-01. In addition, CBP-01 exhibited mutagenic/recombinogenic potential only at the lowest concentration and after biometabolization. Subsequently, in the ETT test, CBP-01 did not demonstrate carcinogenic effect. Lastly, epithelial tumors were identified in flies treated with CARB and CIS, which were modulated by the CBP-01 complex. Therefore, CBP-01 modulates genotoxicity of other compounds and is a promising metal-based drug for the development of a new anticancer agent or for optimization of therapeutic regimens. |
---|---|
Bibliography: | Conflict of Interest: There is a patent resulting from the work reported in this manuscript submitted to the National Institute of Industrial Property of Brazil, process number BR 10 2021 004367 9 Associate Editor: : Catarina Satie Takahashi |
ISSN: | 1415-4757 1678-4685 1678-4685 |
DOI: | 10.1590/1678-4685-gmb-2023-0366 |